T he burden of stroke and cardiovascular disease (CVD) continues to rise across the world [1][2][3]. The Global Burden of Disease study reports that by 2010, high blood pressure had become the leading risk factor globally for both deaths and disability (disabilityadjusted life years), and that ischaemic heart disease and stroke were first and second, respectively, among causes of death across the world [1-3]. Between them, ischaemic heart disease and stroke accounted for 12.9 million deaths, or one in four deaths worldwide, and the majority of these deaths were attributable to high blood pressure.The latest publication from the Global Burden of Disease study drills down on the drivers of these increases, both globally and in 21 regions covering 188 countries, and reports that two dominant factors are responsible, the growth of populations and the ageing of populations that are seen across the globe [4]. These two factors overcome an opposing trend from decreases in age-specific death rates, in almost all regions of the world. However, there are two regions out of the 21, where the gains in age-specific cardiovascular health were sufficient to offset these two demographic factors, and result in an overall decrease in deaths due to CVD -Western Europe and Central Europe, where the total number of CVD deaths fell by 13 and 5%, respectively [4].This issue of the Journal of Hypertension presents a very relevant article from Central Europe, reflecting on our performance in controlling blood pressure in both stroke survivors and in a population sample [5]. Specifically, Cifkova et al.[5] report on 424 survivors of ischaemic stroke, treated in two university hospitals in the Czech Republic, and 414 population controls selected from a 1% random sample of the Czech post-MONICA study, both aged 66 years on average at the time of examination. Confirming the dominant importance of high blood pressure, the authors report that they found hypertension in 92% of stroke survivors and 72% of population controls. Although use of blood pressure-lowering drugs was common in both the groups, 80% in poststroke survivors and 57% in the controls, effective blood pressure control, defined as blood pressure 140/90 mmHg or less, was found only in 43% of stroke survivors and 44% of population controls [5]. The significant predictors of good control were use of angiotensin-converting enzyme inhibitors, number of blood pressure-lowering drugs used, female sex and university education. Similarly, statins were taken by 60% of stroke survivors but a low-density lipoprotein cholesterol of less than 2.5 mmol/l was achieved in less than half. On the other hand, about three-quarters of survivors did take antiplatelet agents, including aspirin. Another disappointment was the fact that about one-third of the survivor group continued to smoke and 40% were obese [5]. The authors conclude that these findings reflect poor implementation of guideline recommendations by clinicians, particularly general practitioners who treat the majority of stroke survivors....